Transaction #18911 · Form 4 · 0001193125-25-317198
Hyperliquid Strategies Inc · Other acquisition · Common Stock
Hyperliquid Strategies Inc · Transacted December 4, 2025 · Filed December 12, 2025
What does this filing report?
An SEC Form 4 filing for Hyperliquid Strategies Inc records an other acquisition involving Common Stock on December 4, 2025. The reported quantity was 95,520. The filing date is December 12, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Hyperliquid Strategies Inc
- Company CIK
- 0002078856
- Security type
- Non-derivative
- Acquisition type
- Other acquisition · Code J
- Quantity acquired
- 95,520
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 95,520
- Ownership description
- Not reported
- SEC acceptance time
- Dec 12, 2025, 11:54 AM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Schamis David Ira ↗
Chief Executive Officer · Director
CIK 0001377409
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- On December 2, 2025, Hyperliquid Strategies Inc (the "Company") completed its previously announced business combination (the "Closing"), pursuant to the Business Combination Agreement, dated as of July 11, 2025 (as amended on September 22, 2025, the "BCA"), by and among the Company, Sonnet BioTherapeutics Holdings, Inc. ("Sonnet"), Rorschach I LLC, TBS Merger Sub Inc. and Rorschach Merger Sub, LLC . In connection with the Closing, Rorschach Capital LLC received an aggregate of 6,580,800 shares of common stock, par value $0.01 per share, of the Company (the "Common Stock"). On December 4, 2025, Rorschach Capital LLC distributed 95,520 shares of Common Stock to Mr. Schamis, a member of Rorschach Capital LLC.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.